Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer: A Triple-Blinded, Randomized Clinical Trial.

IF 1.8 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Iranian Journal of Pharmaceutical Research Pub Date : 2024-12-16 eCollection Date: 2024-01-01 DOI:10.5812/ijpr-152364
Hedyieh Karbasforooshan, Hossein Rahimi, Omid Arasteh, Abolghasem Allahyari, Mehdi Varmaghani, Mahdi Jannati, Vahid Ghavami, Mahmoodreza Jaafari, Sepideh Elyasi
{"title":"Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer: A Triple-Blinded, Randomized Clinical Trial.","authors":"Hedyieh Karbasforooshan, Hossein Rahimi, Omid Arasteh, Abolghasem Allahyari, Mehdi Varmaghani, Mahdi Jannati, Vahid Ghavami, Mahmoodreza Jaafari, Sepideh Elyasi","doi":"10.5812/ijpr-152364","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and oxaliplatin and capecitabine (XELOX) are the most widely used chemotherapy regimens for treating metastatic colorectal carcinoma (CRC). These regimens are associated with various adverse reactions, including neuropathy and hand-foot syndrome (HFS). Silymarin, a flavonoid derived from <i>Silybum marianum</i>, has a wide range of biological activities. It has been used to counteract chemotherapy side effects due to its antioxidant, anti-apoptotic, and anti-inflammatory properties.</p><p><strong>Objectives: </strong>The purpose of this study was to assess the preventive effect of nano-silymarin on neuropathy and HFS induced by the FOLFOX6 and XELOX regimens.</p><p><strong>Methods: </strong>A randomized, triple-blinded, placebo-controlled clinical trial was conducted on 60 patients who were randomly assigned to receive 70 mg capsules containing 15% silymarin nano micelles twice a day after meals, starting from the first day of the first chemotherapy course and continuing for six courses of the XELOX or m-FOLFOX6 regimen. The severity of adverse effects was assessed after the third and sixth courses based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.</p><p><strong>Results: </strong>The median CTCAE scores for HFS and neuropathy were significantly lower in the nano-silymarin group at the end of the third course (P < 0.001). However, the difference remained significant only for HFS at the end of the sixth course (P = 0.022). Additionally, the scores increased significantly in both the placebo and nano-silymarin groups during the therapy (P < 0.05).</p><p><strong>Conclusions: </strong>Nano-silymarin may be considered an adjuvant medication for the prevention of certain chemotherapy-induced adverse reactions. Further research with larger sample sizes and various doses of nano-silymarin is recommended for a more comprehensive evaluation.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"23 1","pages":"e152364"},"PeriodicalIF":1.8000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892790/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5812/ijpr-152364","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and oxaliplatin and capecitabine (XELOX) are the most widely used chemotherapy regimens for treating metastatic colorectal carcinoma (CRC). These regimens are associated with various adverse reactions, including neuropathy and hand-foot syndrome (HFS). Silymarin, a flavonoid derived from Silybum marianum, has a wide range of biological activities. It has been used to counteract chemotherapy side effects due to its antioxidant, anti-apoptotic, and anti-inflammatory properties.

Objectives: The purpose of this study was to assess the preventive effect of nano-silymarin on neuropathy and HFS induced by the FOLFOX6 and XELOX regimens.

Methods: A randomized, triple-blinded, placebo-controlled clinical trial was conducted on 60 patients who were randomly assigned to receive 70 mg capsules containing 15% silymarin nano micelles twice a day after meals, starting from the first day of the first chemotherapy course and continuing for six courses of the XELOX or m-FOLFOX6 regimen. The severity of adverse effects was assessed after the third and sixth courses based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.

Results: The median CTCAE scores for HFS and neuropathy were significantly lower in the nano-silymarin group at the end of the third course (P < 0.001). However, the difference remained significant only for HFS at the end of the sixth course (P = 0.022). Additionally, the scores increased significantly in both the placebo and nano-silymarin groups during the therapy (P < 0.05).

Conclusions: Nano-silymarin may be considered an adjuvant medication for the prevention of certain chemotherapy-induced adverse reactions. Further research with larger sample sizes and various doses of nano-silymarin is recommended for a more comprehensive evaluation.

口服纳米水飞蓟素制剂预防转移性结直肠癌患者XELOX或m-FOLFOX6方案诱导的手足综合征和神经病变的疗效评估:一项三盲、随机临床试验
背景:亚叶酸、氟尿嘧啶和奥沙利铂(FOLFOX)以及奥沙利铂和卡培他滨(XELOX)是治疗转移性结直肠癌(CRC)最广泛使用的化疗方案。这些方案与各种不良反应相关,包括神经病变和手足综合征(HFS)。水飞蓟素是一种从水飞蓟中提取的类黄酮,具有广泛的生物活性。由于其抗氧化、抗细胞凋亡和抗炎的特性,它被用来抵消化疗的副作用。目的:研究纳米水飞蓟素对FOLFOX6和XELOX方案诱导的神经病变和HFS的预防作用。方法:对60例患者进行随机、三盲、安慰剂对照临床试验,从第一个化疗疗程的第一天开始,随机分配每天两次餐后服用含15%水飞蓟素纳米胶束的70 mg胶囊,持续6个疗程的XELOX或m-FOLFOX6方案。根据美国国家癌症研究所不良事件通用术语标准(NCI-CTCAE)第5版,在第三和第六疗程后评估不良反应的严重程度。结果:纳米水飞蓟素组在第三疗程结束时HFS和神经病变的CTCAE中位数评分显著降低(P < 0.001)。然而,只有在第6个疗程结束时,HFS的差异仍然显著(P = 0.022)。此外,安慰剂组和纳米水飞蓟素组在治疗期间得分均显著升高(P < 0.05)。结论:纳米水飞蓟素可作为预防某些化疗不良反应的辅助药物。建议采用更大的样本量和不同剂量的纳米水飞蓟素进行进一步研究,以便进行更全面的评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.40
自引率
6.20%
发文量
52
审稿时长
2 months
期刊介绍: The Iranian Journal of Pharmaceutical Research (IJPR) is a peer-reviewed multi-disciplinary pharmaceutical publication, scheduled to appear quarterly and serve as a means for scientific information exchange in the international pharmaceutical forum. Specific scientific topics of interest to the journal include, but are not limited to: pharmaceutics, industrial pharmacy, pharmacognosy, toxicology, medicinal chemistry, novel analytical methods for drug characterization, computational and modeling approaches to drug design, bio-medical experience, clinical investigation, rational drug prescribing, pharmacoeconomics, biotechnology, nanotechnology, biopharmaceutics and physical pharmacy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信